Skip to content
value.today
Innate Pharma SA logo

Innate Pharma SA

IPHYF
$230 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$10 M
For year ending December-2025
Net income
$-55 M
-545.9% margin
SEC filing
Employees
181
As of December 31, 2024
SEC filing

Innate Pharma SA in brief

Innate Pharma SA is a listed company in the Biotechnology industry, based in France. Its last known market value was $230 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $10 M and a net loss of $55 M. It employs about 181 people. Its shares trade under the symbol IPHYF (EURONEXT).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Innate Pharma SA

Even if the Company completes the necessary preclinical and clinical studies, the marketing approval process is expensive, time-consuming and uncertain and may prevent the Company from obtaining approvals for the commercialization of some or all of its product candidates. If the Company is not able to obtain, or if there are delays in obtaining, required regulatory approvals, in particular in the United States or the European Union, the Company will not be able to commercialize its product candidates, and its ability to generate revenue will be materially impaired.

The research and development of pharmaceutical products is governed by complex regulatory requirements. The regulatory agencies that oversee these requirements have the authority to permit the commencement and maintenance of clinical studies or to temporarily halt or terminate a study. They are entitled to request additional clinical data before authorizing the commencement or resumption of a study, which could result in delays or changes to the product development plan. As the Company advances its product candidates, the Company will be required to consult with these regulatory agencies for regulatory approval and comply with all applicable guidelines, rules and regulations. If the Company fails to do so, the Company may be required to delay or discontinue a clinical study of its product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease its ability to generate sufficient product revenue to maintain its business.

From the company's annual report filed with the US SEC: read the report

Innate Pharma SA timeline

4 events, 1999–2019
  1. 1999
  2. 🏁
    · approximate
    Incorporated as Innate Pharma
  3. 2014
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. •
    Legal Entity Identifier issued
    LEI 9695002Y8420ZB8HJE29 registered.
  6. 2019
  7. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 18 October 2019; shares registered for exchange trading on 10 October 2019.

Events of Innate Pharma SA from the GLEIF LEI register and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$164 M$328 M$492 M$656 M20202021202220232024

World rank over time

▼ down 7,161 places since 2020
2020-01-01: #10002#10,00220202021-01-01: #13152#13,15220212022-01-07: #15287#15,28720222022-12-25: #17543#17,54320222023-07-30: #16798#16,79820232024-01-05: #17163#17,1632024

Rank in France: #187 (Jan 2020) · #240 (Jan 2021) · #223 (Jan 2022) · #247 (Dec 2022) · #240 (Jul 2023) · #230 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-545.9%
Operating margin
-599.5%
Return on equity
—
Liabilities / assets
134.6%
Revenue growth
-53.3%
R&D / revenue
484.2%
Revenue per employee
$56 K
Profit per employee
$-306 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $111M, net income $4M$111MFY18Fiscal year ending Dec 2019: revenue $96M, net income $-23M$96MFY19Fiscal year ending Dec 2020: revenue $80M, net income $-73M$80MFY20Fiscal year ending Dec 2021: revenue $29M, net income $-62M$29MFY21Fiscal year ending Dec 2022: revenue $61M, net income $-61M$61MFY22Fiscal year ending Dec 2023: revenue $67M, net income $-8M$67MFY23Fiscal year ending Dec 2024: revenue $22M, net income $-54M$22MFY24Fiscal year ending Dec 2025: revenue $10M, net income $-55M$10MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$10M-53.3%$-61M$-55M-545.9%
Dec 2024$22M-67.3%$-56M$-54M-245.9%
Dec 2023$67M+10.0%$-14M$-8M-12.3%
Dec 2022$61M+107.5%$-60M$-61M-100.7%
Dec 2021$29M-63.3%$-57M$-62M-213.8%
Dec 2020$80M-16.8%$1M$-73M-91.7%
Dec 2019$96M-13.7%$2M$-23M-24.3%
Dec 2018$111M—$6M$4M3.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-60M$0M$-60M$-0.62—
Dec 2024$-7M$0M$-8M$-0.66—
Dec 2023$-35M$0M$-36M$-0.10—
Dec 2022$-20M$1M$-21M$-0.77—
Dec 2021$-69M$1M$-70M$-0.78—
Dec 2020$-59M$1M$-60M$-0.92—
Dec 2019$39M$1M$38M$-0.35—
Dec 2018$-38M$1M$-39M$0.06—

SEC filings

Official filings of Innate Pharma SA with the US Securities and Exchange Commission.

Annual results

Revenue
$10 M
Operating income
$-61 M
Net income
$-55 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$74 M
Total liabilities
$99 M
Total equity
$-26 M

As of December-2025

Markets and events: Innate Pharma SA#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
123,237
8.92 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 1,376 shares at $1.48
  • : 317 shares at $1.58
  • : 945 shares at $1.46
  • : 45 shares at $1.48
  • : 278 shares at $1.43

Innate Pharma SA scorecard#

Passes 1 of the 11 checks that could be worked out: strongest in growth (1 of 6), weakest in profitability (0 of 4). Fiscal year 2025.

  • Valuationnot known
  • Growth1 of 6
  • Profitability0 of 4
  • Financial health0 of 1
  • Shareholder returnsnot known

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Innate Pharma SA's statements, beside the median of Biotechnology.

Innate Pharma SA: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-599.5%-60.5%
Net margin-545.9%-70.4%
Revenue growth, 3 years a year-44.9%12.9%
Revenue growth-53.3%16.0%
Free cash flow margin-587.2%-61.7%

0of 6on the Piotroski tests of financial strength

  • Revenue fell 53.3% against the year before.
  • Net loss of $55 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$60 million.
  • Shareholders' equity is negative: -$26 million.

Innate Pharma SA: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Innate Pharma SA: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue9.02062582570r85r9444
Research and development445256524750r63r7067
Selling, general and administrative—2018222619r21r1817
Selling and marketing0.50.40.40.70.50.5r0.6r0.50.6
Total costs and expenses6372741157369r84r8884
Operating income−54−52−13−57−481.1r1.6r5.1−40
Interest and finance income8.06.16.94.86.34.9116.02.5
Interest expense and finance costs3.14.01.85.34.06.85.08.411
Income before tax−49−49−7.6−58−45−0.8r7.9r2.7−48
Income tax0000000−0.30.4
Income from continuing operations−49−49−7.6−58−45−0.87.9——
Income from discontinued operations—00−0.1−7.3−63−29——
Net income including minority interests−49−49−7.6−58−53−64−213.0−48
Earnings per share, basic-0.55-0.61-0.09-0.73-0.66-0.81-0.310.05-0.89
Earnings per share, diluted-0.55-0.61-0.09-0.73-0.66-0.81-0.310.05-0.89
Shares, weighted average (basic)908180808079675954
Shares, weighted average (diluted)—818080807967——
Balance sheet
Cash and cash equivalents2866718410413720315299
Short-term investments6.21422171615161517
Receivables125.0563818221915221
Current assets4786148r140138173238320138
Property, plant and equipment———8.510121211r11
Other intangible assets000.41.6r4446978546
Non-current assets162527r59r129134164132118
Total assets63111175r199r267307401451255
Accounts payable151617212930509225
Current liabilities373340r41804512219774
Non-current liabilities486984r104r80r106628795
Retained earnings——————−135−139−104
Total equity−228.85254107156217167r99r
Total liabilities and equity63111175r199r267307401451255
Shares outstanding———80—————
Cash-flow statement
Depreciation and amortization1.42.05.1454.657177.44.4
Share-based compensation2.63.94.34.22.62.53.82.79.8
Cash from operating activities−53−6.9−33r−19r−58−5235−33−48
Capital expenditure−0.1−0.4−0.4−0.5−0.9−0.9−1.3−0.9−3.0
Intangible assets bought00−2.0−0.6−0.4−10−64−0.6−3.1
Cash from investing activities7.39.221r1.9−0.9−13−6224−29
Debt issued0000291.41401.7
Debt repaid−8.9−8.9−2.4−2.0−2.1−2.2−2.0−1.3r−1.2
Shares issued152.90.40.20.50.00.00.1—
Cash from financing activities6.1−6.0−2.0−1.827r−1.278610.9
Exchange-rate effect on cash1.1−0.50.3−0.4−0.50.20.0−0.00.1
Change in cash−38−4.2−14−20r−33r−6651r53−77
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Dec 31, 2025

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Innate Pharma SA
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2013$27 MNo. 1$10 to $50 million6equitySEC

How Innate Pharma SA compares in Biotechnology

  • Revenue$10 M · higher than 44% of 649
  • Net margin-545.9% · higher than 12% of 407
  • Revenue growth-53.3% · higher than 16% of 441

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Innate Pharma SA🇫🇷$230 M—-545.9%-53.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2024
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Innate Pharma SA? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Innate Pharma SA's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Innate Pharma SA? Suggest a correction